2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer

被引：1342

作者：

Hughes, WT

Armstrong, D

Bodey, GP

Bow, EJ

Brown, AE

Calandra, T

Feld, R

Pizzo, PA

Rolston, KVI

Shenep, JL

Young, LS

机构：

[1] St Jude Childrens Res Hosp, Memphis, TN 38105 USA

[2] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[3] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA

[4] Harvard Univ, Sch Med, Boston, MA USA

[5] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA

[6] Kuzell Inst Arthrit, San Francisco, CA USA

[7] Univ Manitoba, Winnipeg, MB, Canada

[8] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada

[9] CHU Vaudois, CH-1011 Lausanne, Switzerland

来源：

CLINICAL INFECTIOUS DISEASES | 2002年 / 34卷 / 06期

关键词：

D O I：

10.1086/339215

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

This article, prepared by the Infectious Diseases Society of America (IDSA) Fever and Neutropenia Guidelines Panel, updates guidelines established a decade ago by the Infectious Disease Society of America for the use of antimicrobial agents to treat neutropenic patients with unexplained fever [1].

引用

收藏

页码：730 / 751

页数：22

相关论文

共 195 条

[151] Is monotherapy for febrile neutropenia still a viable alternative? [J].

Ramphal, R .

CLINICAL INFECTIOUS DISEASES, 1999, 29 (03) :508-514

[152] Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens:: Results of a randomized phase III trial [J].

Ravaud, A ;

Chevreau, C ;

Cany, L ;

Houyau, P ;

Dohollou, N ;

Roché, H ;

Soubeyran, P ;

Bonichon, F ;

Mihura, J ;

Eghbali, H ;

Tabah, I ;

Bui, BN .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (09) :2930-2936

[153] RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR IN THE TREATMENT OF FEBRILE NEUTROPENIA - A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY IN CHILDREN [J].

RIIKONEN, P ;

SAARINEN, UM ;

MAKIPERNAA, A ;

HOVI, L ;

KOMULAINEN, A ;

PIHKALA, J ;

JALANKO, H .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1994, 13 (03) :197-202

[154] IMIPENEM COMPARED WITH CEFTAZIDIME PLUS VANCOMYCIN AS INITIAL THERAPY FOR FEVER IN NEUTROPENIC CHILDREN WITH CANCER [J].

RIIKONEN, P .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1991, 10 (12) :918-923

[155]

ROLSTON KV, 2000, 40 INT C ANT AG CHEM

[156] Pseudomonas aeruginosa -: Still a frequent pathogen in patients with cancer:: 11-year experience at a comprehensive cancer center [J].

Rolston, KVI ;

Tarrand, JJ .

CLINICAL INFECTIOUS DISEASES, 1999, 29 (02) :463-464

[157] New trends in patient management: Risk-based therapy for febrile patients with neutropenia [J].

Rolston, KVI .

CLINICAL INFECTIOUS DISEASES, 1999, 29 (03) :515-521

[158]

ROLSTON KVI, 1999, 39 INT C ANT AG CHEM

[159]

ROLSTON RVI, 2000, 40 INT C ANT AG CHEM

[160] Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: Benefit based on purpose and intensity of cytotoxic therapy [J].

Rotstein, C ;

Bow, EJ ;

Laverdiere, M ;

Ioannou, S ;

Carr, D ;

Moghaddam, N .

CLINICAL INFECTIOUS DISEASES, 1999, 28 (02) :331-340

← 11 12 13 14 15 16 17 18 19 20 →